Understanding the Setup: (SRPT) and Scalable Risk
This article analyzes Sarepta Therapeutics Inc. (NASDAQ: SRPT), highlighting weak sentiment across all horizons which supports a short bias. It identifies a mid-channel oscillation pattern and an exceptional 120.4:1 risk-reward short setup targeting 32.6% downside. The analysis provides AI-generated trading strategies for different risk profiles, including long, breakout, and hedging strategies.
Sarepta's Q1 earnings & sales beat estimates, '26 outlook maintained
Sarepta Therapeutics reported better-than-expected first-quarter earnings and sales, surpassing analyst estimates. Despite the strong Q1 performance, the company reaffirmed its financial outlook for 2026. This indicates confidence in their long-term projections even after a positive start to the year.
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock
Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported strong Q1 2026 earnings and revenue, surpassing analyst expectations, largely due to its gene therapy drug, Elevidys. Despite a revenue dip in Q1 linked to safety concerns and a label update, Sarepta remains confident, citing Elevidys as the sole FDA-approved gene therapy for Duchenne muscular dystrophy with long-term data and a significant market opportunity. The company anticipates sales momentum to rebound later in 2026 and continue into 2027.
Rare Disease Therapeutics Market 2025-2033 | Market Growth
The Rare Disease Therapeutics Market is projected for significant growth between 2025 and 2033, driven by strategic initiatives from key players, technological advancements, and evolving demand patterns. Valued at US$ 135.88 billion in 2023, it is expected to reach US$ 495.27 billion by 2033 with a CAGR of 13.8%. Recent developments include major acquisitions, expanded clinical programs, and advancements in gene and RNA-based therapies by leading pharmaceutical companies.
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) shares surged 35% following positive early clinical data from two siRNA programs, SRP-1001 for facioscapulohumeral muscular dystrophy type I and SRP-1003 for myotonic dystrophy type I. The data showed promising muscle delivery, biomarker activity, and safety, indicating potential for new treatments. The company is anticipated to report strong quarterly earnings and revenue growth, with analysts significantly upgrading EPS estimates, suggesting further stock appreciation.
Sarepta Therapeutics, Inc. - Common Stock (NQ: SRPT
This article provides recent news headlines concerning Sarepta Therapeutics, Inc. (SRPT), a biotechnology company. Key updates include presentations at healthcare conferences, Q1 2026 earnings reports highlighting both beats and revenue dips, and significant stock surges related to clinical data and siRNA pipeline breakthroughs. The news also covers regulatory updates and clinical study advancements for its Duchenne Muscular Dystrophy (DMD) treatments.
We Don't Think Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Should Make Shareholders Too Comfortable
This article analyzes Sarepta Therapeutics' recent earnings report, suggesting that while the reported numbers might seem positive, shareholders shouldn't be overly comfortable. It implies a deeper dive into the financials is needed beyond initial figures to understand the company's true performance or future outlook.
Sarepta Therapeutics stock (US8036071004): Q1 earnings beat estimates amid share price decline
Sarepta Therapeutics reported strong Q1 2026 earnings, with EPS of $3.16 significantly beating analyst expectations of $0.98. Despite this beat, the company's stock has declined 12.5% year-to-date, trading at $18.84 from $21.52. Investors are reportedly concerned about the sustainability of profits, potentially due to one-time items boosting the earnings.
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News
Sarepta Therapeutics (NASDAQ:SRPT) recently reported seemingly strong earnings, but a deeper analysis reveals some concerns. The company has significantly diluted its shares over the past year, impacting earnings per share, and a notable portion of its profit came from "unusual items" which are typically not recurring. These factors suggest that the reported statutory profit might not reflect a sustainable level of profitability for shareholders.
SRPT Stock Price Prediction 2025-2026 | Sarepta Therapeutics Inc Forecast
24/7 Wall St. rates Sarepta Therapeutics Inc (SRPT) as a "HOLD" with a 12-month target price of $17.99, indicating a slight downside from its current price of $18.84. The analysis includes optimistic and conservative scenarios, projecting potential price movements to $27.77 and $14.55 respectively. Long-term forecasts extend to 2031, with a target price of $19.38 and an average price of $19.27 by 2030, reflecting mixed analyst sentiment and various proprietary adjustment factors.
Sarepta Therapeutics (NASDAQ: SRPT) files Form 13F showing 1 entry
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has filed a Form 13F-HR on May 13, 2026, which details one information table entry with a total reported value of $0. The filing, signed by Ryan Wong, Executive Vice President and CFO, indicates no other included managers. This quarterly disclosure outlines stock holdings for large investment managers, offering insights into their portfolios.
Rare-disease genetic medicine firm Sarepta to speak at healthcare investor event
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, announced that its senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, at 8:30 a.m. ET. The presentation will be webcast live on Sarepta's investor relations website and archived for 90 days. The company focuses on Duchenne muscular dystrophy and is expanding its portfolio to include muscle, central nervous system, and cardiac diseases.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta Therapeutics, Inc. announced that its senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, at 8:30 a.m. ET. The presentation will be webcast live on Sarepta's investor relations website and archived for 90 days. Sarepta, a leader in precision genetic medicine for rare diseases, focuses on Duchenne muscular dystrophy and is developing treatments for muscle, central nervous system, and cardiac diseases.
The Technical Signals Behind (SRPT) That Institutions Follow
This article from Stock Traders Daily analyzes Sarepta Therapeutics Inc. (SRPT) using AI models to identify technical signals relevant to institutional trading. It highlights weak near-term and long-term sentiment with a neutral mid-term outlook, and presents three distinct trading strategies: Position Trading (Long), Momentum Breakout, and Risk Hedging (Short). The analysis points to an exceptional risk-reward setup targeting a significant gain with minimal risk.
Sarepta Broadens Beyond Elevidys With siRNA Progress And FDA Milestones
Sarepta Therapeutics (NasdaqGS:SRPT) is expanding its focus beyond the gene therapy Elevidys by advancing siRNA candidates SRP-1001 and SRP-1003 and seeking traditional FDA approvals for AMONDYS 45 and VYONDYS. This strategic shift aims to balance its portfolio with more recurring revenue streams, moving beyond the regulatory complexities and quarter-to-quarter variability associated with Elevidys. For investors, the company's future hinges on the success of these broader pipeline initiatives, their impact on revenue stability, and how they navigate potential earnings declines and market volatility while building on recent profitability.
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5
H.C. Wainwright has reiterated its Sell rating on Sarepta Therapeutics (SRPT.US) and maintained a target price of $5. This indicates a continued bearish outlook from the firm regarding the company's stock performance.
Is Sarepta Therapeutics (SRPT) A Potential Opportunity After Sharp Multi‑Year Share Price Declines?
Sarepta Therapeutics (SRPT) has experienced significant share price declines over multiple years. While a Discounted Cash Flow analysis suggests the stock is undervalued by 71.4%, its current P/E ratio of 33.75x is significantly higher than both the industry average and Simply Wall St's proprietary "Fair Ratio." The article presents bullish and bearish narratives for SRPT, highlighting the importance of individual investor assumptions about clinical and pipeline developments for future valuation.
Sarepta Therapeutics (NasdaqGS:SRPT) Stock Forecast & Analyst Predictions
Sarepta Therapeutics (SRPT) is projected to experience declines in revenue and earnings, with EPS expected to drop by 29.1% annually. Recent analyst updates show price targets decreasing due to revised revenue expectations, safety concerns, and reduced future P/E assumptions for its key product, ELEVIDYS. Despite these challenges, Sarepta is actively advancing its pipeline, including gene therapies for Duchenne muscular dystrophy and siRNA programs for other neurological conditions, and recently reported Q1 2026 earnings that surpassed analyst expectations.
Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35
Wedbush has reiterated its Buy rating for Sarepta Therapeutics (SRPT.US), keeping its target price at $35. This indicates a continued positive outlook on the company's stock performance by the firm.
A Look At Sarepta Therapeutics (SRPT) Valuation After Its First Quarter Profit Turnaround
Sarepta Therapeutics (SRPT) turned profitable in its first quarter, reporting net income of US$330.96 million, despite a revenue decrease. The stock currently trades at an intrinsic discount, with analysts providing a wide range of price targets that on average suggest it is 6% overvalued at $21.65. The article also highlights the company's low P/S ratio compared to its industry and peers, suggesting potential undervaluation if market sentiment improves.
Sarepta tumbles as its gene therapy sales decline further
Sarepta Therapeutics' shares fell over 10% despite its gene therapy Elevidys exceeding Wall Street sales expectations, as quarter-over-quarter sales continued to decline. Analysts suggest investor focus is shifting from Elevidys to Sarepta's early-stage siRNA drug platform due to long-term growth uncertainties and competitive threats. The company, which faced a tumultuous year with setbacks and safety concerns for Elevidys, is now betting on two siRNA drugs licensed from Arrowhead Pharmaceuticals.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics (NASDAQ: SRPT) reported its first-quarter 2026 financial results, with net product revenues of $330.5 million, including $102.0 million from ELEVIDYS and $228.6 million from PMO products. The company achieved GAAP operating income of $358.4 million and non-GAAP operating income of $397.7 million. Key corporate highlights include initial Phase 1/2 data for siRNA candidates SRP-1001 (FSHD1) and SRP-1003 (DM1), enrollment progress for ELEVIDYS in non-ambulatory patients, and regulatory advancements for AMONDYS 45 and VYONDYS 53.
Sarepta says to ‘exercise prudence’ in setting expectations for Elevidys’ recovery
Sarepta Therapeutics has advised caution regarding expectations for the recovery of its Duchenne muscular dystrophy gene therapy, Elevidys, despite current financial strength. The drug faced multiple patient deaths in 2025, leading to FDA restrictions and a boxed warning, which slowed demand. Sarepta is implementing aggressive commercial initiatives and expanding its salesforce to re-energize the market, though executives warn that a full recovery will take time.
Sarepta Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SRPT) 2026-05-06
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its Q1 2026 earnings, reporting an EPS of $3.16, beating estimates by $2.11, and revenue of $730.80M, surpassing expectations by $253.76M despite a slight year-over-year decrease. The company published a slide deck in conjunction with its earnings call.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics reported its first-quarter 2026 financial results, achieving $730.8 million in total revenues and significant operating income. The company highlighted progress in stabilizing its commercial portfolio, advancing its siRNA pipeline with promising early data, and making regulatory advancements for its PMO therapies. Sarepta reiterated its full-year 2026 guidance, projecting total net product revenues of $1.2 - $1.4 billion.
Sarepta faces earnings test as ELEVIDYS slows, siRNA pipeline builds By Investing.com
Sarepta Therapeutics Inc. is facing an important test with its upcoming first-quarter earnings report. Investors will be closely watching the performance of its flagship Duchenne muscular dystrophy drug, ELEVIDYS, which has seen a slowdown due to safety concerns. The company is also pivoting towards its siRNA pipeline, which analysts view as a potential bright spot for future growth.
Sarepta Therapeutics: Q1 Earnings Snapshot
Sarepta Therapeutics Inc. (SRPT) reported a strong first quarter, with net income reaching $331 million and adjusted earnings of $3.16 per share, significantly exceeding analyst expectations of 90 cents per share. The biopharmaceutical company also surpassed revenue forecasts, posting $730.8 million against an estimated $467.9 million. These results indicate a successful financial performance for the company in the first quarter.
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in
As Q1 earnings approach, Sarepta, Amylyx, and Neumora Therapeutics are facing pivotal moments tied to key catalysts. Sarepta anticipates important readouts regarding its Duchenne muscular dystrophy therapies and a potential wider market for Elevidys. Amylyx, after withdrawing its ALS drug, is banking on its acquisition of avexitide for post-bariatric hypoglycemia, while Neumora Therapeutics is looking for positive Phase 3 data for its major depressive disorder drug, navacaprant, and has an obesity asset in its pipeline.
Sarepta Therapeutics Q1 2026 Earnings Preview — May 6, Street Expects $1.05 EPS
Sarepta Therapeutics is expected to report Q1 2026 earnings of $1.05 per share on revenue of $475.0 million by Wall Street analysts. This forecast indicates a significant improvement in profitability compared to the year-ago loss, despite an anticipated decline in revenue. The wide range of analyst estimates for both EPS and revenue highlights considerable uncertainty surrounding the biotechnology company's near-term performance.
Do Sarepta Therapeutics’ (SRPT) Bullish Earnings Forecasts and Vanguard Stake Hint at a Shifting Risk Profile?
Sarepta Therapeutics (SRPT) is drawing attention due to bullish earnings forecasts from Wall Street analysts for its upcoming report and a recent Schedule 13G filing showing Vanguard Capital Management holds a 5.11% passive stake. This combination suggests a potential shift in sentiment and highlights the influence of institutional ownership on the company's outlook. The article explores how this increased optimism, amidst cost-cutting efforts, might reshape Sarepta's investment narrative, particularly concerning the sustainability of its ELEVIDYS treatment and broader pipeline.
Do Sarepta Therapeutics’ (SRPT) Bullish Earnings Forecasts and Vanguard Stake Hint at a Shifting Risk Profile?
Sarepta Therapeutics (SRPT) is drawing attention due to bullish earnings forecasts for its upcoming report, despite projected lower revenues, and a new 5.11% passive stake from Vanguard. This suggests a potential shift in investor sentiment and ownership structure. The company's future hinges on its rare-disease pipeline, particularly ELEVIDYS, navigating safety concerns and operational bottlenecks amidst significant cost cuts in 2025.
Vanguard Capital Management (NASDAQ: SRPT) reports 5.11% stake in Sarepta Therapeutics
Vanguard Capital Management has reported a 5.11% beneficial ownership stake in Sarepta Therapeutics (SRPT), totaling 5,369,116 shares. This passive investment, disclosed via a Schedule 13G filing, indicates Vanguard has sole voting power for 790,881 shares and sole dispositive power for all 5,369,116 shares. The filing underscores that this is a routine disclosure of passive ownership and does not imply control over Sarepta Therapeutics.
M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT
M&T Bank Corp has acquired 83,348 shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for approximately $1.79 million, representing a 0.08% stake in the biotechnology company. Sarepta Therapeutics recently missed its quarterly EPS estimates but exceeded revenue expectations, while analysts provide mixed ratings with an average price target of $32.63. Insider activity also shows a director selling a significant portion of their holdings.
Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday
Sarepta Therapeutics (SRPT) is projected to release its Q1 2026 earnings after market close on Wednesday, May 6th, with analysts expecting an EPS of $0.975 and revenue of $475.6 million. The company's previous quarter saw a significant earnings miss and a 32.7% year-over-year revenue decline, highlighting recent operational challenges and volatility. Despite a brutal 2025, analysts still project a 179% upside with a consensus "Hold" rating and a $32.63 price target.
Vanguard Portfolio Management (NASDAQ: SRPT) holds 6.75M shares (6.43%)
Vanguard Portfolio Management has disclosed its ownership of 6,751,168 shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) common stock, representing 6.43% of the class. This information was filed in a Schedule 13G on April 29, 2026. Vanguard reports sole dispositive power over all 6.75 million shares and sole voting power over 110,476 shares.
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) is expected to report significant year-over-year earnings growth for the quarter ending March 2026, despite projected lower revenues. Analysts anticipate an EPS of $0.90 per share, marking a 126.3% increase, with revenues estimated at $467.85 million, a 37.2% decline. The company's Zacks Earnings ESP of +12.85% combined with a Zacks Rank of #3 suggests a high probability of beating the consensus EPS estimate.
Sarepta’s Elevidys to Remain on Market With New FDA Warning
The FDA announced that Sarepta Therapeutics' gene therapy, Elevidys, will remain on the market but will include a new warning about serious risks. This decision comes after a re-evaluation of the drug's efficacy and safety following concerns raised by an advisory committee. The warning will highlight severe risks such as myocarditis and acute liver injury despite its continued availability for Duchenne muscular dystrophy patients.
[ARS] Sarepta Therapeutics, Inc. SEC Filing
This article reports on an SEC filing (Form ARS) by Sarepta Therapeutics, Inc. (SRPT) on April 24, 2026, noting a low filing impact and neutral sentiment. It provides an overview of the filing details, links to the original document, and includes recent news and other SEC filings related to Sarepta Therapeutics.
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report?
This article analyzes the reasons behind Sarepta Therapeutics' 24.2% stock price increase since its last earnings report. It likely covers factors such as positive drug trial results, regulatory approvals, or financial performance improvements that have boosted investor confidence in SRPT.
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC
Cwm LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 230.8% in Q4, acquiring an additional 167,831 shares, bringing its total to 240,536 shares valued at approximately $5.18 million. Despite this institutional interest and Aberdeen's substantial holding of 2.25 million shares, Sarepta reported a significant EPS miss of -$3.58 against an expectation of -$0.87, although revenue did exceed estimates. The stock is currently trading around $20.68, with analysts holding a consensus "Hold" rating and a price target of $32.63, while insider Stephen Mayo recently sold a portion of his holdings.
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. will report its first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. The company will subsequently host a conference call at 4:30 p.m. E.T. to discuss these results. A webcast of the event will be available on Sarepta's investor relations website, with a replay archived for one year.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts
Sarepta Therapeutics (NASDAQ:SRPT) has received a consensus "Hold" rating from 28 analysts, with an average one-year target price of $32.63. This comes despite the company reporting an EPS miss but a beat on revenue, alongside a 32.7% year-over-year revenue decline. Insider selling and institutional investment activity are also noted, as the company's stock shows a 1-year range of $10.41–$64.80.
How many employees work at Sarepta Therapeutics?
Sarepta Therapeutics, Inc. has 1,162 employees as of December 2025, according to Revelio Labs. This represents a year-over-year growth rate of -38.1%. The company's headcount has fluctuated, with a decline in 2025 following increases in 2024 and 2023.
Opinion: As Duchenne innovation booms, let’s ensure it becomes real progress
Louise Rodino-Klapac from Sarepta Therapeutics discusses the critical questions that must be addressed to ensure that the booming innovation in Duchenne muscular dystrophy translates into tangible and meaningful progress for patients. She emphasizes the need for comprehensive data, long-term durability, alignment of biomarkers with functional outcomes, responsible care, and broader patient access to therapies. The author stresses that real progress involves understanding how therapies perform over time and truly change patients' disease trajectories.
A Look At Sarepta Therapeutics (SRPT) Valuation After Roche’s New Global Elevidys Phase 3 Trial
Roche's decision to launch a new global Phase 3 trial for Elevidys has brought Sarepta Therapeutics (SRPT) back into investor focus. Despite a recent 25.6% gain, the stock has seen a 60% decline over the past year, leading to questions about its current valuation. Analysts have a consensus price target of $21.65, but significant disagreement exists, with projections ranging from $5.0 to $38.0.
Will Roche’s New Global Elevidys Phase 3 Trial Shift Sarepta Therapeutics' (SRPT) Gene Therapy Narrative?
Roche has initiated a new global Phase 3 trial for Elevidys, Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy, aiming for broader European approval. This move could expand Elevidys' international reach, but investors still face near-term risks related to U.S. adoption, safety, and regulatory hurdles. The trial, enrolling about 100 early ambulatory patients over 72 weeks, highlights Roche's ongoing commitment to the therapy and its potential to influence Sarepta's long-term growth and investment narrative.
Roche to start new Elevidys study following setback in Europe
Roche, which holds rights to Sarepta Therapeutics' gene therapy Elevidys outside the U.S., is launching a new global Phase 3 trial for the Duchenne muscular dystrophy treatment. This comes after Europe's main drug regulator issued a negative opinion on Elevidys last year due to insufficient evidence of meaningful benefit. The new study aims to generate additional data to support future approvals and reimbursement in Europe and other countries, though an analyst notes this indicates current data is insufficient and suggests a lengthy timeline to market.
Roche launches new Elevidys study after feedback from European regulator
Roche is initiating a new late-stage study for its gene therapy Elevidys after receiving feedback from the European drug regulator. This phase III study aims to generate the additional placebo-controlled data required for a regulatory re-submission with the European Medicines Agency (EMA), as the therapy had previously failed to gain EMA backing last year. Elevidys is approved in nine countries, including the United States, for ambulatory boys with Duchenne muscular dystrophy (DMD).
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod
Roche has announced a new Phase 3 trial for Elevidys, a Duchenne muscular dystrophy treatment developed with Sarepta Therapeutics. This trial aims to secure European Union approval for the therapy. Elevidys addresses the muscle-wasting disorder Duchenne muscular dystrophy.
Sarepta Therapeutics Stock Surges Above 200-Day Average
Sarepta Therapeutics' stock rose above its 200-day moving average, signaling increased investor confidence despite mixed analyst ratings. This surge is attributed to the biotech firm's progress in developing treatments for rare neuromuscular diseases, particularly Duchenne muscular dystrophy. Investors are keenly watching the company's continued momentum, pipeline developments, and upcoming regulatory milestones.
